Klaver, E. C. http://orcid.org/0000-0003-1082-5527
van Vugt, J. P. P.
Bloem, B. R.
van Wezel, R. J. A.
Nonnekes, J.
Tjepkema-Cloostermans, M. C.
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (ID 16457)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (17619)
Article History
Received: 1 December 2022
Revised: 9 March 2023
Accepted: 9 March 2023
First Online: 21 March 2023
Declarations
:
: Dr. Nonnekes serves at the advisory board of Cue2Walk and Ceriter. Prof. Bloem serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for UCB, Kyowa Kirin, Zambon and the Critical Path Institute (paid to the Institute), has received fees for speaking at conferences from AbbVie, Biogen, UCB, Zambon, Roche, GE Healthcare, Oruen, Novartis and Bial (paid to the Institute), and has received research support from the Netherlands Organization for Health Research and Development, the Michael J Fox Foundation, UCB, the Stichting Parkinson Fonds, Hersenstichting Nederland, de Stichting Woelse Waard, Stichting Alkemade-Keuls, de Maag Lever Darm Stichting, Parkinson NL, Davis Phinney Foundation, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, Nothing Impossible and the Parkinson Vereniging, outside the submitted work. Prof. Bloem does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of the topics in this paper. Prof. van Wezel serves at the Board of the Hemianopia Stichting.
: The study was approved by local ethical committee (MEC-U, trial ID NL68729.044.19) and by the institutional boards at measurement sites. All participants provided written informed consent prior to study participation according to the Declaration of Helsinki.